Upfront 177Lu-PSMA Radioligand Therapy With Concurrent Androgen-deprivation Therapy Producing Dramatic Clinical and Biochemical Response: A Case Report.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
upfront 177Lu-PSMA radioligand therapy combined with androgen-deprivation therapy (ADT)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Radioligand therapy was discontinued after achieving complete molecular and biochemical response. At 8 months of follow-up, the patient remains disease-controlled, supporting the potential value of early 177Lu-PSMA integration in hormone-sensitive metastatic prostate cancer.
A 72-year-old man presented with severe weight loss, anemia, and a PSA level of 73 ng/mL.
APA
Elahifard H, Saber Tanha A, et al. (2026). Upfront 177Lu-PSMA Radioligand Therapy With Concurrent Androgen-deprivation Therapy Producing Dramatic Clinical and Biochemical Response: A Case Report.. Clinical nuclear medicine. https://doi.org/10.1097/RLU.0000000000006411
MLA
Elahifard H, et al.. "Upfront 177Lu-PSMA Radioligand Therapy With Concurrent Androgen-deprivation Therapy Producing Dramatic Clinical and Biochemical Response: A Case Report.." Clinical nuclear medicine, 2026.
PMID
41894578
Abstract
A 72-year-old man presented with severe weight loss, anemia, and a PSA level of 73 ng/mL. Bone scintigraphy and 99mTc-PSMA imaging revealed extensive skeletal metastases. As part of a clinical trial, he received upfront 177Lu-PSMA radioligand therapy combined with androgen-deprivation therapy (ADT). The second cycle of 177Lu-PSMA resulted in complete resolution of all PSMA-avid lesions and a 99% decline in PSA to <0.4 ng/mL. Radioligand therapy was discontinued after achieving complete molecular and biochemical response. At 8 months of follow-up, the patient remains disease-controlled, supporting the potential value of early 177Lu-PSMA integration in hormone-sensitive metastatic prostate cancer.